209728-15-4
中文名稱(chēng)
3-HYDROXYPYRUVIC ACID LITHIUM SALT
英文名稱(chēng)
3-Hydroxypyruvic Acid Lithium Salt
CAS
209728-15-4
分子式
C3H7LiO5
分子量
130.02
MOL 文件
209728-15-4.mol
209728-15-4 結(jié)構(gòu)式
基本信息
中文別名
化合物 T19364 英文別名
Hydroxypyruvic acid lithium hydrateβ-Hydroxypyruvic acid lithium hydrate
3-Hydroxypyruvic acid lithium hydrate
3-HYDROXYPYRUVIC ACID LITHIUM SALT價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2023/03/20 | HY-113013A | 3-HYDROXYPYRUVIC ACID LITHIUM SALT Hydroxypyruvic acid lithium hydrate | 209728-15-4 | 1mg | 1800元 |
| 2023/03/20 | HY-113013A | 3-HYDROXYPYRUVIC ACID LITHIUM SALT Hydroxypyruvic acid lithium hydrate | 209728-15-4 | 5mg | 5400元 |
常見(jiàn)問(wèn)題列表
生物活性
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) 是甘氨酸、絲氨酸和蘇氨酸代謝的中間產(chǎn)物 (intermediate)。Hydroxypyruvic acid lithium hydrate 是絲氨酸-丙酮酸氨基轉(zhuǎn)移酶和乙醛酸還原酶/羥基丙酮酸還原酶的底物 (substrate)。Hydroxypyruvic acid lithium hydrate 參與了二甲基甘氨酸脫氫酶缺乏癥的代謝紊亂途徑。靶點(diǎn)
IC50: intermediate; substrate
體內(nèi)研究
Hydroxypyruvic acid (lithium hydrate) (intravenous injection; 100 mg/ml; slowly over 10 min) increases the 5-h urinary oxalate and glycolate excretion to 0.68% (6.56 μmol) and 0.53% (5.10 μmol) in control rats, in addition, it increases to 2.43% (23.36 μmol) and 0.79% (7.59 μmol) of the dose in the vitamin-B6-deficient rats.